Colchicine, a drug used for gout, may reduce hospitalization time in COVID-19 patients

This is an automated machine translation of an article published by Business Insider in a different language. Machine translations can generate errors or inaccuracies; we will continue the work to improve these translations. You can find the original version here.

New evidence points to colchicine‘s success in improving the condition of coronavirus patients.

Last week an international study led by the Montreal Heart Institute (Canada) reported that colchicine could be positioned as the world’s first oral drug that can be used to treat patients not hospitalized for COVID-19 . According to its results, this drug, normally used to treat gout problems, was able to reduce hospitalizations due to coronavirus by 25% and even deaths by 44%.

The results of a new investigation have found similar findings.

The Brazilian study suggests in its conclusions that colchicine may decrease the body’ s inflammatory response and help prevent damage to blood vessel cells.

The research, published by the British Medical Journal, was conducted between April and August last year. It looked at a total of 75 patients admitted for COVID-19 from moderate to severe cases, who were randomized to receive different levels of colchicine.

Wild saffron is able to reduce COVID-19 deaths by nearly half, according to a new trial in outpatients

The drug was associated with a reduction in hospitalization and ventilator times.

Specifically, on average, colchicine-treated patients required oxygen for 4 days, compared with an average of 6.5 days for those on usual treatment. The average length of hospital admission was one week for the colchicine group compared with an average of 9 days for the other group.

However, the researchers noted that they were unable to link the drug to a reduction in coronavirus mortality, a relationship that the international study was able to establish.

On the other hand, the researchers did not detect any serious side effects, such as heart or liver damage or suppression of the immune system.

If these results are confirmed, this drug could allow not only the improvement of patients but also favor the freeing up of hospital beds, at a time when the rate of contagion is really high.

Even so, the authors call for calm, since the sample on which this new study was based was really small, only 75 people.

Source: Read Full Article